Related Experiment Video

Updated: Jun 14, 2026

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

Differential effects of statins (pravastatin or simvastatin) on ventricular ectopic complexes: Galpha(i2), a possible

C Michael Welzig1, Ho-Jin Park, Jack Naggar

  • 1Molecular Cardiology Research Institute, Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA.

The American Journal of Cardiology
|April 13, 2010
PubMed

Insights

Pravastatin, a statin, reduced ventricular arrhythmias by enhancing parasympathetic heart rate modulation and increasing Galpha(i2) expression. These findings suggest a potential antiarrhythmic mechanism for statins involving the parasympathetic nervous system.

Area of Science:

  • Cardiology
  • Pharmacology
  • Molecular Biology

Background:

  • Retrospective studies indicate statins may possess antiarrhythmic properties.
  • The precise mechanism underlying statins' antiarrhythmic effects remains unclear.
  • Parasympathetic stimulation is known to protect against ventricular arrhythmias.

Purpose of the Study:

  • To investigate the effect of statins on ventricular arrhythmias.
  • To correlate these effects with changes in parasympathetic responsiveness.
  • To examine the relationship with Galpha(i2) protein expression.

Main Methods:

  • A double-blind, randomized crossover study involving pravastatin and simvastatin.
  • 24-hour Holter monitoring for ventricular arrhythmia analysis.
  • Spectral RR interval analysis for parasympathetic modulation assessment.
  • Western blot analysis of Galpha(i2) expression in patient lymphocytes.

Main Results:

  • Pravastatin significantly reduced ventricular premature complexes, couplets, and nonsustained ventricular tachycardia.
  • Pravastatin increased peak high-frequency power fraction, indicating enhanced parasympathetic modulation.
  • Pravastatin treatment led to a significant increase in Galpha(i2) expression.
  • Simvastatin did not show significant effects on ventricular arrhythmias.
  • Changes in arrhythmias correlated negatively with Galpha(i2) and high-frequency fraction.

Conclusions:

  • Pravastatin may decrease cardiac irritability through enhanced parasympathetic responsiveness.
  • Increased Galpha(i2) expression may serve as a molecular marker for this antiarrhythmic effect.
  • These findings elucidate a potential molecular mechanism for the antiarrhythmic action of statins.

More Related Videos

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening10:01

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening

Published on: March 31, 2022

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
G-Protein Gated Ion Channels01:21

G-Protein Gated Ion Channels

GPCRs are primarily responsible for our sense of smell, taste, and vision.  The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory organs,...
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...